πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Viracta Therapeutics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Anixa Biosciences, Inc.

Anixa Biosciences, Inc. logo
Market Cap: Low
Employees: Lowest

Chimeric Endocrine Receptor T-cell Technology, Anti-Viral Drug Candidates, Vaccines

Anixa Biosciences, Inc. is a biotechnology company focused on developing therapies and vaccines for oncology and infectious diseases, including novel CAR-T technologies for ovarian cancer and vaccines for breast and ovarian cancer.

Tags: CAR-T therapy, COVID-19, anti-viral drugs, biotechnology, infectious diseases, oncology, vaccine development

Symbol: ANIX

Recent Price: $2.50

Industry: Biotechnology

CEO: Dr. Amit Kumar Ph.D.

Sector: Healthcare

Employees: 4

Address: 3150 Almaden Expressway, San Jose, CA 95118

Phone: 408 708 9808

Last updated: 2024-12-31

BioAtla, Inc.

BioAtla, Inc. logo
Market Cap: Low
Employees: Low

BA3011

Bio Atla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Their lead product candidate is BA3011, targeting various cancers.

Tags: antibody-based therapeutics, biopharmaceutical, cancer, clinical stage, solid tumor

Symbol: BCAB

Recent Price: $0.59

Industry: Biotechnology

CEO: Dr. Jay M. Short Ph.D.

Sector: Healthcare

Employees: 65

Address: 11085 Torreyana Road, San Diego, CA 92121

Phone: 858 558 0708

Last updated: 2024-12-31

Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

AT-527

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics for viral infections, with a lead product candidate AT-527 for COVID-19 treatment.

Tags: COVID-19, antiviral, biopharmaceutical, clinical-stage, therapeutics

Symbol: AVIR

Recent Price: $3.33

Industry: Biotechnology

CEO: Dr. Jean-Pierre Sommadossi Ph.D.

Sector: Healthcare

Employees: 75

Address: 125 Summer Street, Boston, MA 02110

Phone: 857 284 8891

Leadership

  • Jean-Pierre Sommadossi, PhD, FOUNDER, CHAIRMAN & CEO
  • Nancy Agrawal, PhD, Executive VP, Preclinical Development
  • Jonae Barnes, Senior VP, Investor Relations & Corporate Communications
  • Bruce Belanger, PhD, Senior VP, Biostatistics
  • Andrea Corcoran, CFO & Executive VP, Legal
  • Adam DeZure, MD, VP, Clinical Development
  • James MB Evans, PhD, VP, CMC Manufacturing
  • Wayne Foster, EXECUTIVE VP, Chief Accounting Officer
  • Kerry Gagnon, VP, Head of Quality
  • Steven Good, EXECUTIVE VP, PRECLINICAL SCIENCE
  • Janet Hammond, MD, PhD, CHIEF DEVELOPMENT OFFICER
  • Arantxa Horga, MD, Chief Medical Officer
  • Qi Huang, Senior VP, Virology
  • Laura Ishak, Senior VP, Clinical Operations
  • Ariyapadi Krishnaraj, VP, Marketing
  • Adel Moussa, PhD, EXECUTIVE VP, CHEMISTRY
  • Shari Noble, VP, Deputy General Counsel
  • Keith Pietropaolo, Executive VP, Clinical Sciences and Project Management
  • Brian Rowe, VP, Business Development
  • Marc Van Hulle, VP, Finance
  • John Vavricka, CHIEF COMMERCIAL OFFICER
  • Alex Vo, PhD, VP, DMPK
  • Jayanthi Wolf, PhD, Executive VP, Regulatory Affairs
  • Xiao-Jian Zhou, PhD, EXECUTIVE VP, EARLY STAGE DEVELOPMENT

Last updated: 2024-12-31

Novavax, Inc.

Novavax, Inc. logo
Market Cap: High
Employees: Medium

NVX-Co V2373

Novavax, Inc. is a biotechnology company focused on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Their vaccine candidates include NVX-Co V2373, Nano Flu, and Res Vax. The company operates collaboratively with Takeda Pharmaceutical Company Limited on COVID-19 vaccine development.

Tags: COVID-19, biotechnology, clinical trials, infectious diseases, vaccines

Symbol: NVAX

Recent Price: $7.93

Industry: Biotechnology

CEO: Mr. John Charles Jacobs M.B.A.

Sector: Healthcare

Employees: 1543

Address: 21 Firstfield Road, Gaithersburg, MD 20878

Phone: 240 268 2000

Last updated: 2024-12-31

Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

zilovertamab, ONCT-216, ONCT-808, ONCT-534

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.

Tags: CAR-T, ROR1, antibody, biopharmaceutical, cancer therapy, clinical-stage, oncology

Symbol: ONCT

Recent Price: $0.53

Industry: Biotechnology

CEO: Dr. James B. Breitmeyer M.D., Ph.D.

Sector: Healthcare

Employees: 27

Address: 12230 El Camino Real, San Diego, CA 92130

Phone: 858 434 1113

Last updated: 2024-12-31

Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

TN-201, TN-301, TN-401

Tenaya Therapeutics, Inc. is a biotechnology company that discovers, develops, and delivers therapies for heart disease using cellular regeneration, gene therapy, and precision medicine platforms.

Tags: biotechnology, gene therapy, heart disease, precision medicine, therapeutics

Symbol: TNYA

Recent Price: $1.45

Industry: Biotechnology

CEO: Mr. Faraz Ali M.B.A.

Sector: Healthcare

Employees: 140

Address: 171 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 650 825 6900

Last updated: 2024-12-31

Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

AVTX-002, AVTX-007, AVTX-801

Avalo Therapeutics, Inc. is a clinical-stage precision medicine company focused on discovering, developing, and commercializing targeted therapeutics for patients with unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases.

Tags: clinical trials, immuno-oncology, immunology, precision medicine, rare genetic diseases, therapeutics

Symbol: AVTX

Recent Price: $7.80

Industry: Biotechnology

CEO: Dr. Garry A. Neil M.D.

Sector: Healthcare

Employees: 19

Address: 540 Gaither Road, Rockville, MD 20850

Phone: 410 522 8707

Leadership

  • Garry A. Neil, MD, Chairman of the Board and Chief Executive Officer
  • Mittie Doyle, MD, FACR, Chief Medical Officer
  • Chris Sullivan, Chief Financial Officer
  • Paul Varki, Chief Legal Officer
  • Lisa Hegg PhD, Senior Vice President, Program Management and Corporate Infrastructure and Clinical Operations
  • Colleen Matkowski, Senior Vice President, Global Regulatory Affairs and Quality Assurance
  • Dino C. Miano, PhD, Senior Vice President, CMC and Technical Operations
  • June Almenoff, MD, PhD, President and Chief Medical Officer
  • Mitchell Chan, Chief Financial Officer
  • Jonathan Goldman, MD, CEO
  • Aaron Kantoff, Managing Partner
  • Gilla Kaplan, PhD, Independent Director
  • Samantha Truex, CEO

Last updated: 2024-12-31

Kintara Therapeutics, Inc.

Kintara Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

VAL-083, REM-001

Kintara Therapeutics is a clinical stage drug development company focused on developing and commercializing anti-cancer therapies for drug-resistant solid tumors.

Tags: REM-001, VAL-083, anti-cancer therapies, clinical stage, drug development

Symbol: KTRA

Recent Price: $0.22

Industry: Biotechnology

CEO: Mr. Jeffrey A. Bacha B.Sc., M.B.A.

Sector: Healthcare

Employees: 1

Address: 12707 High Bluff Drive, San Diego, CA 92130

Phone: 858 350 4364

Leadership

  • Robert E. Hoffman, President, CEO, CFO and Chairman of the Board
  • Greg A. Johnson, (Acting) Head of Operations
  • Laura Johnson, Director
  • Tamara A. Favorito, Director
  • Robert J. Toth, Jr., M.B.A., Director

Last updated: 2024-12-31

Maravai LifeSciences Holdings, Inc.

Maravai LifeSciences Holdings, Inc. logo
Market Cap: High
Employees: Medium

Nucleic Acids and Biologics Safety Testing Products

Maravai Life Sciences Holdings, Inc. is a life sciences company that provides products for drug therapies, diagnostics, novel vaccines, and research on human diseases, serving both the United States and international markets.

Tags: Biologics Safety, Biopharmaceutical, Gene Therapy, Life Sciences, Molecular Diagnostics, Nucleic Acids

Symbol: MRVI

Recent Price: $5.51

Industry: Biotechnology

CEO: Mr. William E. Martin III

Sector: Healthcare

Employees: 580

Address: 10770 Wateridge Circle, San Diego, CA 92121

Phone: 858 546 0004

Last updated: 2024-12-31

Nkarta, Inc.

Nkarta, Inc. logo
Market Cap: Low
Employees: Low

NKX101 and NKX019

Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cell therapies for the treatment of cancer. The company specializes in cellular immunotherapy using chimeric antigen receptors on natural killer cells to target tumor antigens.

Tags: NK cells, biopharmaceutical, cancer treatment, cell therapy, clinical trials, immunotherapy

Symbol: NKTX

Recent Price: $2.32

Industry: Biotechnology

CEO: Mr. Paul J. Hastings

Sector: Healthcare

Employees: 150

Address: 6000 Shoreline Court, South San Francisco, CA 94080

Phone: 415 582 4923

Last updated: 2024-12-31

NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ANA001

A clinical-stage biotechnology company developing therapies for neurodegenerative, infectious, and cardiometabolic diseases.

Tags: biotechnology, cardiometabolic diseases, clinical trials, infectious diseases, neurodegenerative diseases

Symbol: NRBO

Recent Price: $2.36

Industry: Biotechnology

CEO: Mr. Hyung-Heon Kim

Sector: Healthcare

Employees: 8

Address: 200 Berkeley Street, Boston, MA 02116

Phone: 857 702 9600

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Nuvalent, Inc.

Nuvalent, Inc. logo
Market Cap: Highest
Employees: Low

NVL-520 and NVL-655

Nuvalent, Inc. is a clinical stage biopharmaceutical company that develops therapies for patients with cancer, focusing on brain-penetrant inhibitors for ROS1 and ALK.

Tags: ALK inhibitor, ROS1 inhibitor, biopharmaceutical, cancer therapies, clinical trials

Symbol: NUVL

Recent Price: $77.87

Industry: Biotechnology

CEO: Dr. James R. Porter Ph.D.

Sector: Healthcare

Employees: 115

Address: One Broadway, Cambridge, MA 02142

Phone: 857 357 7000

Last updated: 2024-12-31

Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

Tavalisse

Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases.

Tags: biotechnology, cancer, drug development, hematologic disorders, immune diseases

Symbol: RIGL

Recent Price: $16.47

Industry: Biotechnology

CEO: Mr. Raul R. Rodriguez

Sector: Healthcare

Employees: 147

Address: 1180 Veterans Boulevard, South San Francisco, CA 94080

Phone: 650 624 1100

Last updated: 2024-12-31

TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

therapeutics for cancer

TRACON Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing cancer therapeutics, including clinical stage products like envafolimab, YH001, TRC102, and TJ004309, with collaboration agreements with various biopharmaceutical companies.

Tags: TJ004309, TRC102, YH001, biopharmaceutical, cancer therapeutics, clinical trials, envafolimab

Symbol: TCON

Recent Price: $0.03

Industry: Biotechnology

CEO: Mr. Craig R. Jalbert CIRA

Sector: Healthcare

Employees: 17

Address: 4350 La Jolla Village Drive, San Diego, CA 92122

Phone: 858 550 0780

Last updated: 2024-12-31

Vincerx Pharma, Inc.

Vincerx Pharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

VIP152

Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company focused on researching and developing therapies to address unmet medical needs for cancer treatment in the United States. Their lead product candidate, VIP152, is a cyclin-dependent kinase-9 inhibitor for advanced cancer.

Tags: biopharmaceutical, cancer treatment, clinical-stage, oncology, therapy development

Symbol: VINC

Recent Price: $0.33

Industry: Biotechnology

CEO: Dr. Ahmed M. Hamdy M.D.

Sector: Healthcare

Employees: 42

Address: 260 Sheridan Avenue, Palo Alto, CA 94306

Phone: 650 800 6676

Last updated: 2024-12-31

Vir Biotechnology, Inc.

Vir Biotechnology, Inc. logo
Market Cap: Medium
Employees: Medium

Sotrovimab (VIR-7832), VIR-2218, VIR-3434, VIR-2482, VIR-1111

Vir Biotechnology, Inc. is a commercial-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases, including COVID-19, hepatitis B, influenza A, and HIV.

Tags: COVID-19, HIV, biotechnology, hepatitis B, immunology, infectious diseases, influenza, therapeutics

Symbol: VIR

Recent Price: $7.33

Industry: Biotechnology

CEO: Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.

Sector: Healthcare

Employees: 587

Address: 499 Illinois Street, San Francisco, CA 94158

Phone: 415 906 4324

Leadership

  • Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer and Director
  • Jeff Calcagno, M.D., Executive Vice President and Chief Business Officer
  • Vanina de Verneuil, J.D., Executive Vice President, General Counsel and Corporate Secretary
  • Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head Oncology
  • Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer
  • Jenny Gumm, Ed.D., MBA, Executive Vice President, Chief Human Resources Officer
  • Aine Hanly, Ph.D., Executive Vice President and Chief Technology Officer
  • Jason O’Byrne, MBA, Executive Vice President and Chief Financial Officer
  • Jennifer Eileen Towne, Ph.D., Executive Vice President and Chief Scientific Officer
  • Arran Attridge, Senior Vice President Corporate Communications
  • Antonio Lanzavecchia, M.D., Senior Vice President and Senior Research Fellow
  • Amalio Telenti, M.D, Ph.D., Executive Vice President and Senior Research Fellow

Last updated: 2024-12-31

Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

N/A

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases, with targets including respiratory syncytial virus, SARS-Co V-2, human metapneumovirus, and hepatitis B virus.

Tags: SARS-Co V-2, biotechnology, hepatitis B virus, liver diseases, pharmaceuticals, respiratory syncytial virus, small molecule drugs, viral infections

Symbol: ENTA

Recent Price: $5.85

Industry: Biotechnology

CEO: Dr. Jay R. Luly Ph.D.

Sector: Healthcare

Employees: 145

Address: 500 Arsenal Street, Watertown, MA 02472

Phone: 617 607 0800

Leadership

  • Jay R. Luly, Ph.D., President, Chief Executive Officer and Director
  • Tara L. Kieffer, Ph.D., Chief Product Strategy Officer
  • Matthew P. Kowalsky, J.D., Chief Legal Officer
  • Brendan Luu, Chief Business Officer
  • Paul J. Mellett, Chief Financial and Administrative Officer
  • Yat Sun Or, Ph.D., Chief Scientific Officer
  • Scott T. Rottinghaus, M.D., Chief Medical Officer
  • Bruce L.A. Carter, Ph.D., Chairman of the Board
  • Mark G. Foletta, Board Member
  • Yujiro S. Hata, Board Member
  • Kristine Peterson, Board Member
  • Lesley Russell, MBChB, MRCPb, Board Member
  • Terry Vance, Board Member

Last updated: 2024-12-31

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. logo
Market Cap: Low
Employees: Lowest

NXP800, NXP900

Nuvectis Pharma, Inc., is a biopharmaceutical company that focuses on developing precision medicines for treating serious unmet medical needs in oncology. It is working on products like NXP800, a heat shock factor 1 pathway inhibitor, and NXP900, a drug candidate targeting Proto-oncogene c-Src and YES1 kinases.

Tags: NXP800, NXP900, biopharmaceutical, oncology, precision medicine

Symbol: NVCT

Recent Price: $5.14

Industry: Biotechnology

CEO: Mr. Ron Bentsur M.B.A.

Sector: Healthcare

Employees: 13

Address: 1 Bridge Plaza, Fort Lee, NJ 07024

Phone: 201 614 3150

Last updated: 2024-12-31

Viracta Therapeutics, Inc.

Viracta Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Nana-val

Viracta Therapeutics, Inc. is a precision oncology company focused on developing drugs for the treatment of virus-associated malignancies, with a lead product candidate Nana-val in clinical trials for Epstein-Barr virus-positive lymphoma and other related conditions.

Tags: EBV+ lymphoma, biotech, clinical trials, oncology, pharmaceuticals, virus-associated malignancies

Symbol: VIRX

Recent Price: $0.16

Industry: Biotechnology

CEO: Mr. Mark Andrew Rothera

Sector: Healthcare

Employees: 40

Address: 2533 South Coast Highway 101, Cardiff-by-the-Sea, CA 92007

Phone: 858 400 8470

Leadership

  • Mark Rothera, President and Chief Executive Officer
  • Darrel P. Cohen, M.D., Ph.D., Chief Medical Officer
  • Ayman Elguindy, Ph.D., Chief Scientific Officer
  • Michael Faerm, MBA, Chief Financial Officer
  • Cheryl Madsen, Senior Vice President, Regulatory
  • Patric Nelson, MBA, Senior Vice President, Business Development & Corporate Strategy
  • Biljana Nadjsombati, Pharm.D., Senior Vice President, Pharmaceutical Development
  • Violetta Akopian, Ph.D., Vice President, Quality Assurance
  • Ruby Cheema, Vice President, Portfolio and Program Management
  • Mark A. McCamish, M.D., Ph.D., Strategic Advisor
  • Roger J. Pomerantz, M.D., Chairman of the Board
  • Jane F. Barlow, M.D., MPH, MBA, Director
  • Flavia Borellini, Ph.D., Director
  • Jane Chung, R.Ph., Director
  • Thomas E. Darcy, CPA, Director
  • Sam Murphy, Ph.D., Director
  • Ivor Royston, M.D., Director
  • Stephen Rubino, Ph.D., MBA, Director
  • Barry J. Simon, M.D., Director
  • Douglas V. Faller, M.D., Ph.D., Scientific Founder and Chairman, Scientific Advisory Board
  • Robert Baiocchi, M.D., Ph.D., Scientific Advisor
  • Gavin Giovannoni, MBBCh, Ph.D., FCP (Neurol., SA), FRCP, FRCPath, Scientific Advisor
  • Carl June, M.D., Scientific Advisor
  • Shannon Kenney, M.D., Scientific Advisor
  • Ronald Levy, M.D., Scientific Advisor
  • Pierluigi Porcu, M.D., Scientific Advisor
  • Daniel D. Von Hoff, M.D., F.A.C.P. FASCO, FAACR, Scientific Advisor
  • Lawrence Young, Ph.D., Scientific Advisor

Last updated: 2024-12-31